OPEC+ has agreed in principle to raise oil production by 137K barrels per day starting in November, according to published ...

I see extreme undervaluation in certain high-yield dividend stocks facing temporary macro headwinds. Prices are far below ...

Procter & Gamble faces weak growth, fading pricing power, and overvaluation despite buybacks and brand strength. Find out why ...

Treasuries remain steady as IEI ETF weathers deficits, shutdown risks, and policy shifts, offering stability in transitionary ...

Gauzy develops light-sensitive films and ADAS systems, showing strong growth, global reach, and technological moats. Read why ...

APA Corporation transformed its Alaska project from a high-risk bet into a compelling appraisal opportunity. Read why APA ...

SoundThinking trades at a deep discount to peers, reflecting risks tied to its reliance on ShotSpotter and recent contract ...

A couple of double-digit-yielding dividend stocks look sustainable even if long-term interest rates remain elevated. Learn ...

Biotech is outperforming the S&P 500 and NASDAQ as M&A heats up and Q4 tailwinds emerge, signaling more upside ahead. Read ...

Sanofi’s pharma focus, strong Dupixent growth, and valuation discount position it for upside amid buybacks and rising ...

The Fed’s employment-first stance and reliance on R-Star risk credibility as inflation stays elevated and growth remains ...

Q2 is nearing profitability with strong moats and growth, but overvaluation limits upside despite solid fundamentals. Read ...